{"title":"Role of Helicobacter Pylori Eradication in Pregnant Women with Hyperemesis Gravidarum","authors":"M. Ahmed, A. Elsayed, A. Soliman","doi":"10.21608/EBWHJ.2017.3218","DOIUrl":null,"url":null,"abstract":"Objective: The aim of this research is to detect the role of eradication of Helicobacter pylori in pregnant women withhyperemesis gravidarum (HG) using modified, high dose, non-teratogenic dual therapy.Study design: Randomized controlled trial.Patients and methods: The study included 156 pregnant women suffering from HG with positive fecal antigen test forHelicobacter pylori. Participants were divided randomly into two groups: group A that received the traditional management for HG (diet instructions, intravenous fluids, electrolyte replacement, antiemetics and vitamins supplementation), and group B that received the previous management for HG plus adding eradication dual therapy for Helicobacter pylori in form of Lansoprazole 30 mg TID + Amoxicillin 1 g TID for 2 weeks and the clinical response to both lines of management was evaluated in both groups two weeks after the start of management.Results: There is a statistically significant difference between both groups as regard clinical response to the used regimen with more clinical improvement in group B.Conclusion: There is an association between Helicobacter pylori infection and hyperemesis gravidarum, allowing us toconclude that Helicobacter pylori should be considered as one of the risk factors of HG. Screening for Helicobacter pylorishould be added to the investigations of HG, especially if prolonged or refractory to the traditional management. Modified, high dose, non-teratogenic dual therapy for eradication of Helicobacter pylori could be considered to relieve HG in intractable cases with negligible side effects.","PeriodicalId":224226,"journal":{"name":"Evidence Based Womenʼs Health Journal","volume":"60 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2017-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Evidence Based Womenʼs Health Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/EBWHJ.2017.3218","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4
Abstract
Objective: The aim of this research is to detect the role of eradication of Helicobacter pylori in pregnant women withhyperemesis gravidarum (HG) using modified, high dose, non-teratogenic dual therapy.Study design: Randomized controlled trial.Patients and methods: The study included 156 pregnant women suffering from HG with positive fecal antigen test forHelicobacter pylori. Participants were divided randomly into two groups: group A that received the traditional management for HG (diet instructions, intravenous fluids, electrolyte replacement, antiemetics and vitamins supplementation), and group B that received the previous management for HG plus adding eradication dual therapy for Helicobacter pylori in form of Lansoprazole 30 mg TID + Amoxicillin 1 g TID for 2 weeks and the clinical response to both lines of management was evaluated in both groups two weeks after the start of management.Results: There is a statistically significant difference between both groups as regard clinical response to the used regimen with more clinical improvement in group B.Conclusion: There is an association between Helicobacter pylori infection and hyperemesis gravidarum, allowing us toconclude that Helicobacter pylori should be considered as one of the risk factors of HG. Screening for Helicobacter pylorishould be added to the investigations of HG, especially if prolonged or refractory to the traditional management. Modified, high dose, non-teratogenic dual therapy for eradication of Helicobacter pylori could be considered to relieve HG in intractable cases with negligible side effects.
目的:探讨改良、大剂量、非致畸双重治疗在妊娠剧吐(HG)孕妇中根除幽门螺杆菌的作用。研究设计:随机对照试验。患者和方法:本研究纳入156例幽门螺杆菌粪便抗原检测阳性的HG孕妇。参与者被随机分为两组:A组采用传统的HG治疗方法(饮食指导、静脉输液、电解质补充、止吐药和维生素补充),B组采用原有的HG治疗方法加幽门螺杆菌根除双重治疗,即兰索拉唑30mg TID +阿莫西林1g TID,疗程2周,两组在治疗开始2周后评价两种治疗方法的临床疗效。结果:两组患者对使用方案的临床反应差异有统计学意义,b组临床改善较多。幽门螺杆菌感染与妊娠剧吐之间存在一定的相关性,提示幽门螺杆菌是HG的危险因素之一。在对HG的调查中应增加幽门螺杆菌的筛查,特别是在传统治疗方法长期或难治的情况下。改良的、高剂量的、无致畸性的根除幽门螺杆菌的双重治疗可以考虑缓解顽固性病例的HG,副作用可以忽略不计。